Nemifitide: Research & Studies

Research Overview#

Nemifitide has a moderate evidence base for a peptide antidepressant, including multiple randomized clinical trials, phase 1 pharmacokinetic studies, and preclinical efficacy data. The compound has been tested in over 430 subjects across 12 clinical trials. However, the pivotal trials are relatively small, and published results show mixed efficacy that correlates with plasma drug exposure.

Phase 2 Clinical Trial (Feighner et al., 2000)#

The key efficacy study (PMID: 11099750) randomized 52 outpatients with major depression to nemifitide 0.2 mg/kg or placebo administered subcutaneously for 5 consecutive days. The overall intent-to-treat analysis showed trends toward improvement, but statistically significant antidepressant effects were observed specifically in the subgroup of patients who achieved adequate plasma concentrations (above the minimum effective concentration). Nemifitide was well tolerated with no significant adverse effects.

Pharmacokinetic Studies (Nicolau et al., 2002)#

Phase 1 studies (PMID: 11891671) established that nemifitide is rapidly absorbed (Cmax at ~10 minutes) and eliminated (half-life 15-30 minutes) after SC injection, with dose-proportional pharmacokinetics across the 18-320 mg range. The short half-life contrasts with the multi-day pharmacodynamic effect, suggesting mechanism-based persistence of therapeutic activity.

Preclinical Evidence (Overstreet et al., 2004)#

In the Flinders Sensitive Line rat model of depression (PMID: 14985919), nemifitide showed antidepressant-like effects with an unusual biphasic dose-response curve. Effects were significant at low and high doses but absent at intermediate doses. Onset was rapid (5 days), comparable to desipramine.

Evidence Quality Assessment#

The evidence level is moderate based on the availability of randomized placebo-controlled clinical data. However, limitations include small sample sizes, post-hoc pharmacokinetic stratification, mixed overall results, and the absence of published phase 3 data.

Research Evidence Context#

Nemifitide belongs to the Neuropeptide category of research peptides. The research evidence for Nemifitide spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for Nemifitide:

A double-blind, placebo-controlled, efficacy, safety, and pharmacokinetic study of INN 00835, a novel antidepressant peptide, in the treatment of major depression#

Authors: Feighner JP, Hendrickson G, Miller L, Stern W (2000) — Journal of Affective Disorders

Phase 2 randomized double-blind placebo-controlled trial in 52 outpatients with major depression. Nemifitide 0.2 mg/kg SC daily for 5 days showed significant antidepressant effects in patients with adequate plasma concentrations.

Key Findings:

• 52 patients randomized to nemifitide 0.2 mg/kg or placebo SC for 5 days
• Significant improvement on HAMD, MADRS, CGI, and VAS in patients above MEC
• Rapid onset of antidepressant effect within 5-7 days
• No significant adverse effects reported
• Plasma concentration was a key determinant of response

Limitations: Small sample size; post-hoc pharmacokinetic stratification; response correlated with plasma levels suggesting variable bioavailability

Clinical pharmacokinetic studies with INN 00835 (nemifitide), a novel pentapeptide antidepressant#

Authors: Nicolau G, Bhagavan H, Engasser JL, Stern W (2002) — Biopharmaceutics and Drug Disposition

Phase 1 pharmacokinetic characterization of nemifitide in healthy volunteers. Doses from 18-320 mg SC demonstrated rapid absorption and elimination with dose-proportional pharmacokinetics.

Key Findings:

• Rapid absorption with Cmax at ~10 minutes after SC injection
• Short half-life of 15-30 minutes
• Dose-proportional AUC and Cmax across 18-320 mg range
• No significant safety concerns at any dose level tested

Limitations: Healthy volunteers only; single and short multiple-dose studies; no long-term exposure data

Antidepressant-like effects of a novel pentapeptide, nemifitide, in an animal model of depression#

Authors: Overstreet DH, Hlavka J, Feighner JP, et al. (2004) — Psychopharmacology

Preclinical evaluation of nemifitide in the Flinders Sensitive Line rat model of depression. Demonstrated antidepressant-like effects with biphasic dose-response and rapid onset comparable to desipramine.

Key Findings:

• Significant antidepressant effects at low (0.025-0.3 mg/kg) and high (3-15 mg/kg) doses
• Inactive at intermediate doses (0.4-2.4 mg/kg), showing biphasic response
• Rapid onset after 5 days of treatment, matching desipramine
• Long-lasting effects similar to fluoxetine but unlike desipramine

Limitations: Animal model; unusual biphasic dose-response curve; forced swim test limitations

Evidence Quality Assessment#

The overall evidence level for Nemifitide is classified as moderate. There is meaningful clinical evidence from Phase 2 or similar trials, though larger confirmatory studies may be needed.

Research Gaps and Future Directions#

The following gaps in the current evidence base for Nemifitide have been identified:

• Phase 3 results have not been published in peer-reviewed literature
• Mechanism of the biphasic dose-response relationship is unexplained
• Variable bioavailability complicates dose-response assessment
• Long-term safety and efficacy data beyond short treatment courses
• Comparison with modern antidepressant treatments (e.g., ketamine, esketamine)

Addressing these research gaps will be important for establishing a more complete understanding of Nemifitide's therapeutic potential and safety profile.

Related Reading#

• Nemifitide overview and research guide
• Nemifitide dosing protocols
• Nemifitide molecular structure